Sobi is set to present a comprehensive portfolio of clinical study updates at the upcoming International Society on Thrombosis and Haemostasis (ISTH) Congress in Washington from June 21-25, 2025. The company will showcase ten presentations highlighting advancements in treatments for rare blood disorders.
Innovative Treatments for Hemophilia and ITP
Among the key presentations, Sobi will unveil new data on avatrombopag’s effectiveness in treating children with immune thrombocytopenia (ITP). Additionally, the outcomes of using efanesoctocog alfa in surgical settings will be detailed, providing insights into its long-term benefits for hemophilia patients. These studies underscore Sobi’s commitment to addressing unmet medical needs in rare blood conditions.
Collaborative Efforts and Future Directions
Lydia Abad-Franch, MD, Head of R&D and Medical Affairs, emphasized the importance of collaboration and knowledge sharing at ISTH. Sobi’s partnership with Sanofi will also be highlighted, showcasing joint efforts in developing and commercializing treatments like Alprolix and Elocta/Eloctate. This collaboration aims to enhance global access to innovative therapies for patients worldwide.
- Avatrombopag shows consistent response across diverse patient profiles in ITP treatment.
- Efanesoctocog alfa demonstrates significant improvements in surgical outcomes for hemophilia A.
- Long-term studies reveal positive joint health outcomes in hemophilia patients using efanesoctocog alfa.
The presentations scheduled span various formats, including oral and poster sessions, ensuring comprehensive dissemination of research findings. Attendees will gain valuable insights into the latest clinical practices and emerging therapies that could redefine treatment paradigms for thrombosis and hemostasis disorders.
Looking ahead, Sobi’s contributions at ISTH 2025 are expected to pave the way for enhanced therapeutic strategies and foster further collaboration within the medical community. By presenting robust clinical data, Sobi reaffirms its role as a leader in developing treatments that significantly improve patient outcomes in rare hematological conditions.
For healthcare professionals and stakeholders, the congress will offer a unique opportunity to engage with cutting-edge research and explore new avenues for patient care. Sobi’s participation underscores its dedication to advancing medical science and delivering innovative solutions to complex health challenges.
Ultimately, the insights shared at ISTH 2025 will not only highlight Sobi’s latest advancements but also contribute to the broader understanding and management of rare blood disorders, fostering a collaborative environment aimed at improving lives globally.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
